Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New shareholder

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Apr 19, 2024 6:07am

127 Views

Post# 35997476

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder

Is it a 1B-2B buyout or 4B+? We all hope it's a 4B+. But what is playing against us ... time is running fast and BP probably see us as a possible cheap target. Do we have in Matt the man of the situation to get the best deal? Have a Good friday all.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market